Aspire Biopharma (NASDAQ:ASBP) Issues Earnings Results

Aspire Biopharma (NASDAQ:ASBP) released its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, reports. The business had revenue of $0.00 million during the quarter.

Aspire Biopharma Stock Up 8.4%

Shares of ASBP stock opened at $1.03 on Wednesday. The business has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $5.96. Aspire Biopharma has a 12-month low of $0.55 and a 12-month high of $35.01. The firm has a market cap of $2.77 million, a P/E ratio of -0.05 and a beta of 0.88.

Hedge Funds Weigh In On Aspire Biopharma

Large investors have recently modified their holdings of the company. CIBC Bancorp USA Inc. bought a new stake in Aspire Biopharma in the 3rd quarter worth approximately $28,000. XTX Topco Ltd grew its position in Aspire Biopharma by 853.2% during the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares in the last quarter. 19.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on ASBP. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aspire Biopharma has an average rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.